Mode
Text Size
Log in / Sign up
Phase 3 Completed N=119 Randomized Quadruple-blind Treatment

Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis

Source: ClinicalTrials.gov NCT02618759 ↗
Enrolled (actual)
119
Serious AEs
0.0%
Results posted
Dec 2018
Primary outcomePrimary: Number of Patients in Each Treatment That Have Clinical Success Based on IGA at Day 28 ± 2 — 10; 3 Participants — p=0.0745
◆ Published Evidence
No publication linked

No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.

Summary

The purpose of this study is to evaluate the therapeutic efficacy and safety of DSXS compared to a Placebo (vehicle) in patients with mild to moderate plaque psoriasis.

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Patients in Each Treatment That Have Clinical Success Based on IGA at Day 28 ± 2
10; 3 0.0745
PRIMARY
Number of Patients in Each Treatment That Have Treatment Success Based on TLSS at Day 28 ± 2
8; 4 0.2310
SECONDARY
Number of Patients in Each Treatment That Have Clinical Success Based on IGA at Day 28 ± 2 (Patients With a Baseline IGA Score of 3)
8; 3 0.1059
SECONDARY
Number of Patients in Each Treatment That Have Treatment Success Based on TLSS at Day 28 ± 2 (Patients With a Baseline IGA Score of 3)
4; 3 0.6962
SECONDARY
Number of Patients in Each Treatment That Have Clinical Success Based on IGA at Day 28 ± 2 (Patients With a Baseline IGA Score of 2)
2; 0 1.0000
SECONDARY
Number of Patients in Each Treatment That Have Treatment Success Based on TLSS at Day 28 ± 2 (Patients With a Baseline IGA Score of 2)
16; 10 0.1044

Eligibility Criteria

Inclusion Criteria

  • male and non-pregnant females, 12 years of age or older, with a confirmed diagnosis of mild to moderate plaque psoriasis

Exclusion Criteria

  • patient is< 12 years old.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02618759). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search